Annual EBITDA
-$71.02 M
-$4.77 M-7.21%
December 31, 2023
Summary
- As of February 12, 2025, JANX annual EBITDA is -$71.02 million, with the most recent change of -$4.77 million (-7.21%) on December 31, 2023.
- During the last 3 years, JANX annual EBITDA has fallen by -$64.46 million (-981.86%).
- JANX annual EBITDA is now -1786.43% below its all-time high of -$3.77 million, reached on December 31, 2019.
Performance
JANX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$35.33 M
-$22.02 M-165.33%
September 30, 2024
Summary
- As of February 12, 2025, JANX quarterly EBITDA is -$35.33 million, with the most recent change of -$22.02 million (-165.33%) on September 30, 2024.
- Over the past year, JANX quarterly EBITDA has dropped by -$20.02 million (-130.73%).
- JANX quarterly EBITDA is now -2715.30% below its all-time high of -$1.25 million, reached on September 30, 2020.
Performance
JANX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$83.88 M
-$20.02 M-31.35%
September 30, 2024
Summary
- As of February 12, 2025, JANX TTM EBITDA is -$83.88 million, with the most recent change of -$20.02 million (-31.35%) on September 30, 2024.
- Over the past year, JANX TTM EBITDA has dropped by -$10.60 million (-14.47%).
- JANX TTM EBITDA is now -6283.79% below its all-time high of -$1.31 million, reached on March 31, 2020.
Performance
JANX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
JANX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -7.2% | -130.7% | -14.5% |
| 3 y3 years | -981.9% | -224.9% | -298.8% |
| 5 y5 years | -1786.4% | -2588.9% | -6283.8% |
JANX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -116.4% | at low | -165.3% | at low | -155.6% | at low |
| 5 y | 5-year | -1786.4% | at low | -2715.3% | at low | -6283.8% | at low |
| alltime | all time | -1786.4% | at low | -2715.3% | at low | -6283.8% | at low |
Janux Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$35.33 M(+165.3%) | -$83.88 M(+31.3%) |
| Jun 2024 | - | -$13.32 M(-32.2%) | -$63.86 M(-9.8%) |
| Mar 2024 | - | -$19.63 M(+25.8%) | -$70.83 M(-0.3%) |
| Dec 2023 | -$71.02 M(+7.2%) | -$15.61 M(+1.9%) | -$71.02 M(-3.1%) |
| Sep 2023 | - | -$15.31 M(-24.5%) | -$73.28 M(-3.2%) |
| Jun 2023 | - | -$20.28 M(+2.3%) | -$75.74 M(+4.3%) |
| Mar 2023 | - | -$19.83 M(+11.0%) | -$72.62 M(+9.6%) |
| Dec 2022 | -$66.25 M | -$17.86 M(+0.5%) | -$66.25 M(+7.2%) |
| Sep 2022 | - | -$17.77 M(+3.6%) | -$61.81 M(+12.6%) |
| Jun 2022 | - | -$17.15 M(+27.4%) | -$54.92 M(+24.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$13.46 M(+0.3%) | -$44.00 M(+34.1%) |
| Dec 2021 | -$32.82 M(+399.9%) | -$13.43 M(+23.4%) | -$32.82 M(+56.0%) |
| Sep 2021 | - | -$10.88 M(+74.3%) | -$21.04 M(+84.3%) |
| Jun 2021 | - | -$6.24 M(+174.2%) | -$11.41 M(+51.7%) |
| Mar 2021 | - | -$2.27 M(+38.2%) | -$7.53 M(+14.6%) |
| Dec 2020 | -$6.57 M(+74.4%) | -$1.65 M(+31.2%) | -$6.57 M(+33.5%) |
| Sep 2020 | - | -$1.25 M(-46.6%) | -$4.92 M(+34.3%) |
| Jun 2020 | - | -$2.35 M(+78.8%) | -$3.66 M(+178.8%) |
| Mar 2020 | - | -$1.31 M | -$1.31 M |
| Dec 2019 | -$3.77 M | - | - |
FAQ
- What is Janux Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Janux Therapeutics?
- What is Janux Therapeutics annual EBITDA year-on-year change?
- What is Janux Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Janux Therapeutics?
- What is Janux Therapeutics quarterly EBITDA year-on-year change?
- What is Janux Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Janux Therapeutics?
- What is Janux Therapeutics TTM EBITDA year-on-year change?
What is Janux Therapeutics annual EBITDA?
The current annual EBITDA of JANX is -$71.02 M
What is the all time high annual EBITDA for Janux Therapeutics?
Janux Therapeutics all-time high annual EBITDA is -$3.77 M
What is Janux Therapeutics annual EBITDA year-on-year change?
Over the past year, JANX annual EBITDA has changed by -$4.77 M (-7.21%)
What is Janux Therapeutics quarterly EBITDA?
The current quarterly EBITDA of JANX is -$35.33 M
What is the all time high quarterly EBITDA for Janux Therapeutics?
Janux Therapeutics all-time high quarterly EBITDA is -$1.25 M
What is Janux Therapeutics quarterly EBITDA year-on-year change?
Over the past year, JANX quarterly EBITDA has changed by -$20.02 M (-130.73%)
What is Janux Therapeutics TTM EBITDA?
The current TTM EBITDA of JANX is -$83.88 M
What is the all time high TTM EBITDA for Janux Therapeutics?
Janux Therapeutics all-time high TTM EBITDA is -$1.31 M
What is Janux Therapeutics TTM EBITDA year-on-year change?
Over the past year, JANX TTM EBITDA has changed by -$10.60 M (-14.47%)